23-MULTI-59-LTI(LTSA1-P02): A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors (BOLSTER)

Grants and Contracts Details

StatusActive
Effective start/end date7/18/237/18/25

Funding

  • Lisata Therapeutics Incorporated: $50,123.00